In This Article:
-
Net Pyrukynd Revenue (Q4 2024): $10.7 million, a 51% increase from $7.1 million in Q4 2023.
-
Cost of Sales (Q4 2024): $1.3 million.
-
R&D Expenses (Q4 2024): $82.8 million, an increase of $5.3 million from Q4 2023.
-
SG&A Expenses (Q4 2024): $51.7 million, an increase of $16.4 million from Q4 2023.
-
Cash Equivalents and Marketable Securities (End of Q4 2024): Approximately $1.5 billion.
-
Milestone Payments (2024): Total of $1.1 billion, including $905 million from Royalty Pharma and $200 million from Servier.
Release Date: February 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Agios Pharmaceuticals Inc (NASDAQ:AGIO) reported a 51% increase in net Pyrukynd revenue for Q4 2024 compared to the same quarter in 2023.
-
The company is preparing for two additional commercial launches, with potential approval and launch of Pyrukynd in thalassemia expected in September 2025 and in sickle cell disease in 2026.
-
Agios has a robust early and mid-stage pipeline poised for clinical advancement, including the completion of enrollment in the phase 3 rise up study for sickle cell disease.
-
The company has a strong balance sheet with approximately $1.5 billion in cash, equivalents, and marketable securities, providing financial independence for future growth.
-
Agios announced positive top-line results from the Activate Kids Phase 3 trial of Mitapivat in pediatric patients with PK deficiency, marking its first pediatric clinical program for a rare hemolytic anemia.
Negative Points
-
Agios Pharmaceuticals Inc (NASDAQ:AGIO) expects flat revenues for PK deficiency in 2025 compared to 2024, indicating limited growth in this area.
-
The company noted that Q4 2024 revenues were higher due to year-end stocking and adjustments, which are not expected to repeat in Q1 2025.
-
There are concerns about liver toxicity in the sickle cell trial, leading to changes in the monitoring protocol.
-
The launch in the Gulf region, particularly Saudi Arabia, is expected to take time due to the need for formulary access and healthcare system navigation.
-
Agios faces challenges in pediatric development, which is complex and requires significant logistical considerations.
Q & A Highlights
Q: What is Agios Pharmaceuticals' strategy for updating the investment community on the safety profile of Mitapivat, especially concerning hepatocellular injury? A: Sarah Gheuens, Chief Medical Officer, stated that if there are any changes to the safety profile of Mitapivat, the company will update the investment community as they have done in the past when new safety information became available.